[go: up one dir, main page]

BR9811037A - Utilização de ligantes mhc classe ii como coadjuvante para vacinação e de lag-3 no tratamento do câncer - Google Patents

Utilização de ligantes mhc classe ii como coadjuvante para vacinação e de lag-3 no tratamento do câncer

Info

Publication number
BR9811037A
BR9811037A BR9811037-3A BR9811037A BR9811037A BR 9811037 A BR9811037 A BR 9811037A BR 9811037 A BR9811037 A BR 9811037A BR 9811037 A BR9811037 A BR 9811037A
Authority
BR
Brazil
Prior art keywords
lag
vaccination
mhc class
class
ligands
Prior art date
Application number
BR9811037-3A
Other languages
English (en)
Inventor
Frederic Triebel
Original Assignee
Roussy Inst Gustave
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Applied Research Systems filed Critical Roussy Inst Gustave
Publication of BR9811037A publication Critical patent/BR9811037A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>"UTILIZAçãO DE LIGANTES MHC CLASSE II COMO COADJUVANTE PARA VACINAçãO E DE LAG-3 NO TRATAMENTO DO CâNCER"<D>. A presente invenção refere-se ao uso de ligante MHC classe II, tal como CD4 e LAG-3 para fabricação de um medicamento para prevenir ou tratar condições patológicas envolvendo uma resposta imune específica para antígeno, bem como o uso de LAG-3 em imunoterapia de câncer. A invenção também refere-se a composição farmacêutica compreendendo uma quantidade eficaz de um antígeno capaz de induzir uma resposta imune específica para antígeno, juntamente com uma quantidade eficaz de um ligante MHC classe II, onde o dito ligante MHC classe II está presente como um agente semelhante a coadjuvante.
BR9811037-3A 1997-07-25 1998-07-23 Utilização de ligantes mhc classe ii como coadjuvante para vacinação e de lag-3 no tratamento do câncer BR9811037A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97401800A EP0893507A1 (en) 1997-07-25 1997-07-25 Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
PCT/EP1998/004621 WO1999004810A2 (en) 1997-07-25 1998-07-23 Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment

Publications (1)

Publication Number Publication Date
BR9811037A true BR9811037A (pt) 2000-08-01

Family

ID=8229825

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811037-3A BR9811037A (pt) 1997-07-25 1998-07-23 Utilização de ligantes mhc classe ii como coadjuvante para vacinação e de lag-3 no tratamento do câncer

Country Status (20)

Country Link
US (2) US6410509B1 (pt)
EP (3) EP0893507A1 (pt)
JP (1) JP4723722B2 (pt)
KR (1) KR100603075B1 (pt)
CN (1) CN1184320C (pt)
AT (2) ATE324455T1 (pt)
AU (1) AU753738B2 (pt)
BR (1) BR9811037A (pt)
CA (2) CA2293805C (pt)
DE (2) DE69841866D1 (pt)
DK (1) DK1002108T3 (pt)
EA (3) EA200300092A1 (pt)
EE (1) EE200000039A (pt)
ES (1) ES2262242T3 (pt)
HK (1) HK1030014A1 (pt)
IL (2) IL134212A0 (pt)
NO (1) NO20000378L (pt)
PT (1) PT1002108E (pt)
UA (1) UA75322C2 (pt)
WO (1) WO1999004810A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1295895B1 (en) * 2001-09-19 2011-08-10 Institut Gustave Roussy Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
WO2004078928A2 (en) 2003-02-28 2004-09-16 The Johns Hopkins University T cell regulation
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
FR2868781B1 (fr) 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP2044949A1 (en) * 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
WO2012062861A1 (en) 2010-11-10 2012-05-18 Laboratorios Leti, S.L. New adjuvant
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN103751778B (zh) * 2014-01-28 2016-09-28 复旦大学 3′-脱氧腺苷在制备广谱疫苗增效的免疫佐剂中的应用
ME03558B (me) 2014-03-14 2020-07-20 Novartis Ag Molekuli anti-lag-3 antiтela i njihove upotrebe
JP6423889B2 (ja) 2014-10-07 2018-11-14 サイトリミック株式会社 Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
US9827308B2 (en) 2014-12-10 2017-11-28 Wisconsin Alumni Research Foundation Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade
GB201500374D0 (en) * 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
EP3269733B1 (en) 2015-03-09 2020-06-17 Cytlimic Inc. Peptide derived from gpc3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
AU2016244570B2 (en) * 2015-04-07 2020-08-27 Nec Corporation Medicine
CA2984643A1 (en) 2015-05-13 2016-11-17 Agenus Inc. Vaccines for treatment and prevention of cancer
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
US10265379B2 (en) 2015-09-16 2019-04-23 Annabelle Rodriguez Oquendo Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
EP3349790A1 (en) 2015-09-18 2018-07-25 Rijksuniversiteit Groningen Long chain inulin for stimulating an immune response
JP6998880B2 (ja) * 2016-10-11 2022-02-10 サイトリミック株式会社 医薬
CN108204958A (zh) * 2016-12-19 2018-06-26 伊缪泰普有限公司 结合测定
EP3784688A2 (en) 2018-04-26 2021-03-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
JP2022502435A (ja) * 2018-09-27 2022-01-11 ジェノセア バイオサイエンシーズ， インコーポレイテッド 治療方法
JP2020138940A (ja) 2019-02-28 2020-09-03 テルモ株式会社 治療方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226414A (en) * 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
EP0431045A4 (en) * 1988-08-22 1991-10-30 Us Commerce Retroviral vectors expressing soluble cd4; a gene therapy for aids
JPH02231083A (ja) * 1988-08-31 1990-09-13 Eisai Co Ltd 組換ナチュラルキラー細胞活性化因子
CA2011299A1 (en) * 1989-03-03 1990-09-03 Franklin Volvovitz Aids therapy
EP0394827A1 (en) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
CA2153593C (en) * 1993-01-26 2010-04-13 David B. Weiner Compositions and methods for delivery of genetic material
SE510135C2 (sv) * 1994-05-05 1999-04-19 Berol Nobel Ab Vattenhaltig suspension av en cellulosaeter, sätt för dess framställning samt komposition
ZA953629B (en) * 1994-05-06 1996-11-05 Roussy Inst Gustave Soluble polypeptidic fragments of lag-3 protein method of production thereof therapeutic composition anti-idiotype antibodies
CA2194488A1 (en) * 1994-08-05 1996-02-15 Tod Paul Holler Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
JP2001506122A (ja) * 1994-12-07 2001-05-15 エフ．ホフマン−ラ ロシュ アーゲー 免疫抑制作用を有するモノクローナル抗体断片
PL320922A1 (en) * 1994-12-23 1997-11-10 Om Lab Sa Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes
EP0869803B1 (en) * 1995-12-28 2003-04-16 The Johns Hopkins University School Of Medicine Allogeneic paracrine cytokine tumor vaccines

Also Published As

Publication number Publication date
IL134212A0 (en) 2001-04-30
EA200000161A1 (ru) 2000-10-30
EP0893507A1 (en) 1999-01-27
UA75322C2 (en) 2006-04-17
EP1002108A2 (en) 2000-05-24
US20020192195A1 (en) 2002-12-19
US7109026B2 (en) 2006-09-19
WO1999004810A2 (en) 1999-02-04
EA200200565A1 (ru) 2002-10-31
CN1265149A (zh) 2000-08-30
ES2262242T3 (es) 2006-11-16
DE69834330T2 (de) 2007-03-29
EA003740B1 (ru) 2003-08-28
US6410509B1 (en) 2002-06-25
CN1184320C (zh) 2005-01-12
JP2001510806A (ja) 2001-08-07
DE69834330D1 (de) 2006-06-01
EP1698701A1 (en) 2006-09-06
IL134212A (en) 2012-03-29
EA005405B1 (ru) 2005-02-24
CA2293805C (en) 2011-05-03
ATE478956T1 (de) 2010-09-15
KR100603075B1 (ko) 2006-07-20
EE200000039A (et) 2000-10-16
AU9254798A (en) 1999-02-16
CA2732570C (en) 2014-11-18
ATE324455T1 (de) 2006-05-15
JP4723722B2 (ja) 2011-07-13
NO20000378D0 (no) 2000-01-25
HK1030014A1 (en) 2001-04-20
NO20000378L (no) 2000-01-25
EA200300092A1 (ru) 2003-06-26
CA2732570A1 (en) 1999-02-04
EP1002108B1 (en) 2006-04-26
KR20010021706A (ko) 2001-03-15
AU753738B2 (en) 2002-10-24
EP1698701B1 (en) 2010-08-25
PT1002108E (pt) 2006-09-29
CA2293805A1 (en) 1999-02-04
DK1002108T3 (da) 2006-08-21
DE69841866D1 (de) 2010-10-07
WO1999004810A3 (en) 1999-07-08

Similar Documents

Publication Publication Date Title
BR9811037A (pt) Utilização de ligantes mhc classe ii como coadjuvante para vacinação e de lag-3 no tratamento do câncer
Carpentier et al. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice
Shibaki et al. Induction of skewed Th1/Th2 T‐cell differentiation via subcutaneous immunization with Freund's adjuvant
DK1225870T3 (da) Sammensætning og fremgangsmåde til cancerantigenimmunterapi
Lewis Therapeutic cancer vaccines: using unique antigens
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
ATE106013T1 (de) Arzneimittelfreisetzungssystem aus glucan und adjuvant.
RU95108231A (ru) Glp-1-молекулярный комплекс, фармацевтическая композиция и способ получения комплекса
ATE314095T1 (de) Virusähnliche partikel zur induktion von autoantikörpern
ATE389712T1 (de) Krebs immuntherapie mit semi-allogenen zellen
DK1082131T3 (da) Immunoregulator
Garaci Thymosin α1: a historical overview
ATE418344T1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
HUP0004780A2 (hu) Prosztaglandin agonisták felhasználása merevedési rendellenességek vagy impotencia kezelésében
DE60027905D1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
MXPA03010261A (es) Metodos para tratar cancer.
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
BR9807332A (pt) Antìgenos de leishmania para utilização na terapia e diagnóstico de leishmaniose
MY127452A (en) Vaccines.
IT1277926B1 (it) Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire
NL192326B (nl) Werkwijze voor het bereiden van een geneesmiddel, waarbij een gezuiverd, ontgift endotoxine samen met een drager en eventueel andere toevoegingen in een voor therapeutische toediening geschikte vorm wordt gebracht.
Tourani et al. Subcutaneous (SC) interleukin-2 (IL-2) plus alpha interferon (IFN-α) and 5 fluororacil (5 FU) in out-patients (pts) with metastatic renal cell carcinoma (MRCC). Scapp II trial

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: INSTITUT GUSTAVE ROUSSY (FR) , LABORATOIRES SERONO

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: INSTITUT GUSTAVE ROUSSY (FR) , MERCK SERONO S.A. (

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 11; ART. 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A (S) 17A ANUIDADE (S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2320 DE 23/06/2015.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]